Related Experiment Video

Updated: Jul 15, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network

Lori J Ducharme1, Hannah K Knudsen, Paul M Roman

  • 1Institute for Behavioral Research, University of Georgia, Athens, GA 30602-2401, USA. lorid@uga.edu

Journal of Substance Abuse Treatment
|May 8, 2007
PubMed

Insights

Involvement in clinical trials networks significantly boosts adoption of new treatments like buprenorphine. However, organizational factors primarily drive the uptake of other innovations, such as motivational incentives.

Area of Science:

  • Implementation Science
  • Health Services Research
  • Addiction Treatment

Background:

  • Facilitating the integration of evidence-based treatments into clinical practice is a key challenge.
  • Research networks offer a potential pathway for driving organizational innovation and treatment adoption.
  • Understanding factors influencing the diffusion of novel interventions is critical for improving patient care.

Purpose of the Study:

  • To investigate the impact of participation in research networks on the adoption of new treatment techniques.
  • To examine whether direct exposure to clinical trials influences the uptake of buprenorphine and motivational incentives.
  • To identify key predictors of organizational innovation in addiction treatment programs.

Main Methods:

  • Analysis of data from participating Clinical Trials Network (CTN) programs and external treatment programs.
  • Statistical modeling to assess the influence of exposure to clinical trials on the adoption of specific interventions.
  • Control for organizational characteristics to isolate the effect of research network involvement.

Main Results:

  • Direct exposure to buprenorphine clinical trials within the CTN significantly increased the likelihood of its subsequent adoption.
  • Adoption of voucher-based motivational incentives was primarily explained by existing organizational characteristics, not trial exposure.
  • Treatment innovation adoption is multifactorial, influenced by exposure, resources, innovation type, and diffusion stage.

Conclusions:

  • Participation in research networks, specifically exposure to trials, is a significant driver for adopting certain evidence-based treatments like buprenorphine.
  • The adoption pathway for different innovations may vary, with some being more influenced by network participation and others by inherent organizational factors.
  • Findings highlight the importance of considering network engagement alongside organizational capacity when promoting treatment innovation.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Crossover Experiments01:16

Crossover Experiments

Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...